FBDD – Fragment Based Drug Discovery – A fast route for development of new drugs

Sprint Bioscience is a drug discovery company operating in the preclinical area of the drug discovery process. The company develops oncology therapeutics targeting cancer metabolism.

Sprint Bioscience’s business strategy involves out-licensing or collaborating at an early stage of drug discovery to ensure that projects are developed with a focus on current and relevant market needs.

With its highly efficient fragment based drug discovery platform, Sprint Bioscience can rapidly identify molecules with properties that are suitable for drug development. These molecules provide a firm basis for the drug discovery programs. In an iterative process that includes: protein science, fragment screening, medicinal chemistry, X-ray crystallography and relevant biology studies; Sprint Bioscience transform them into quality candidate drugs ready to enter the development process.

In addition, Sprint Bioscience offers via its subsidiary Gene2Lead™ full lead generation services including experienced project management.